Primecap Management 13F: Adds $14M to Illumina (ILMN) Stake

Primecap Management has increased its stake in Illumina, Inc. (NasdaqGS: ILMN) by 3.9%, according to its latest 13F filing with the SEC. The firm added 77,620 shares, bringing its total holdings to 2,067,299 shares valued at approximately $374.4 million. This filing reflects Primecap's position as of the end of the reporting period.

What Changed in Primecap Management's Illumina, Inc. Position

Primecap Management boosted its position in Illumina by 3.9%. The firm now holds 2,067,299 shares, up from 1,989,679 shares previously. The value of the stake is about $374.4 million.

Other Institutional Activity in Illumina, Inc.

Other major investors also adjusted their positions in Illumina. BlackRock, Inc. increased its holdings by 701,913 shares, ending with 19,023,590 shares valued at around $2.34 billion, marking a 3.8% increase. Capital World Investors, however, reduced its stake by 4,551,213 shares, resulting in a 22.6% decrease, leaving it with 15,549,960 shares worth about $1.92 billion. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, holding 6,823,654 and 6,594,836 shares, respectively. State Street Corp also increased its holdings by 239,230 shares, a 3.9% rise, to 6,429,344 shares valued at approximately $792.5 million.

Illumina, Inc. Stock Down 32.4%

Shares of Illumina, Inc. traded near $181.10 on Wednesday. The company has a market cap of $26.6 billion, with a P/E ratio of 31.91 and a forward P/E of 29.64. Its beta is 1.49, indicating higher volatility compared to the market. The 52-week range for the stock is $88.00 to $182.84, with a 50-day moving average of $149.97 and a 200-day moving average of $128.97. Illumina maintains a current ratio of 1.75 and a quick ratio of 1.23, with a debt-to-equity ratio of 95.07.

Recent Earnings

Illumina reported revenue of approximately $4.39 billion, reflecting a growth rate of 4.8%. The company's net margin stands at 19.4%, with a return on equity of 33.8%. Earnings per share (EPS) came in at $5.51. The next earnings report is expected on July 30, 2026.

Insider Buying and Selling at Illumina, Inc.

Several insider transactions took place at Illumina. On June 25, 2026, Chief Legal Officer Scott Davies sold 615 shares at $180 each under a planned trading plan. Daniel Skovronsky purchased 1,674 shares at an average price of $164.28 on June 16, 2026. SVP and Chief People Officer Patricia Leckman sold 783 shares at $162.59 and 784 shares at $162.08 on June 5 and June 2, 2026, respectively, both under planned sales. Keith Meister sold 235,000 shares at $163.63 on June 1, 2026, outside of a planned trading plan.

Analysts Set New Price Targets

Analysts have mixed views on Illumina. On June 29, 2026, Guggenheim maintained a 'buy' rating with a $200 price target. Bernstein reinstated coverage with a 'hold' rating and a $185 target on June 26, 2026. Barclays maintained a 'sell' rating with a $145 target on June 24, 2026. JP Morgan upgraded the stock to 'buy' with a $185 price target on June 10, 2026. The consensus recommendation is 'buy', with a mean target price of $151.68.

About Illumina, Inc.

Illumina, Inc., headquartered in San Diego, California, is a leader in the healthcare sector, specifically in diagnostics and research. The company provides sequencing and array-based solutions for genetic and genomic analysis across various regions, including the Americas, Europe, and Asia. Illumina's products serve a wide range of customers, from genomic research centers to consumer genomics companies. Led by CEO Jacob Thaysen, the company employs approximately 8,600 people.

Bottom Line

Primecap Management's recent increase in its Illumina holdings reflects continued interest in the company. Investors track these changes as part of broader market strategies. Remember, 13F filings show past positions and might not indicate current holdings.